Forma Therapeutics Holdings Inc.

24.97-0.6800-2.65%Vol 226.68K1Y Perf -36.23%
Apr 19th, 2021 16:00 DELAYED
BID24.96 ASK24.97
Open25.50 Previous Close25.65
Pre-Market- After-Market-
 - -  - -%
Target Price
60.40 
Analyst Rating
— — 0.00
Potential %
141.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.18B 
Earnings Rating
Price Range Ratio 52W %
7.27 
Earnings Date
30th Mar 2021

Today's Price Range

24.6026.13

52W Range

22.5156.33

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-9.86%
1 Month
-18.80%
3 Months
-31.96%
6 Months
-48.97%
1 Year
-36.23%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FMTX24.97-0.6800-2.65
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.79-0.6813.92
Q03 2020-0.65-0.67-3.08
Q02 2020-0.59-4.58-676.27
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.79
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume226.68K
Shares Outstanding47.37M
Trades Count4.09K
Dollar Volume29.58M
Avg. Volume470.34K
Avg. Weekly Volume335.13K
Avg. Monthly Volume499.97K
Avg. Quarterly Volume503.14K

Forma Therapeutics Holdings Inc. (NASDAQ: FMTX) stock closed at 24.97 per share at the end of the most recent trading day (a -2.65% change compared to the prior day closing price) with a volume of 226.88K shares and market capitalization of 1.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Forma Therapeutics Holdings Inc. CEO is Frank D. Lee.

The one-year performance of Forma Therapeutics Holdings Inc. stock is -36.23%, while year-to-date (YTD) performance is -28.45%. FMTX stock has a five-year performance of %. Its 52-week range is between 22.51 and 56.33, which gives FMTX stock a 52-week price range ratio of 7.27%

Forma Therapeutics Holdings Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 1.97, a price-to-sale (PS) ratio of 203.83, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -17.16%, a ROC of -14.27% and a ROE of -18.45%. The company’s profit margin is -%, its EBITDA margin is -1 559.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Forma Therapeutics Holdings Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.79 for the next earnings report. Forma Therapeutics Holdings Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Forma Therapeutics Holdings Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Forma Therapeutics Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Forma Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Forma Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.18, ATR14 : 2.66, CCI20 : -121.11, Chaikin Money Flow : 0.14, MACD : -3.46, Money Flow Index : 49.16, ROC : -10.89, RSI : 29.01, STOCH (14,3) : 33.15, STOCH RSI : 0.00, UO : 46.33, Williams %R : -66.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Forma Therapeutics Holdings Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Forma Therapeutics Holdings Inc.

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are FT-4202, FT-7051, FT-8225, and others.

CEO: Frank D. Lee

Telephone: +1 617 679-1970

Address: 500 Arsenal Street, Watertown 02472, MA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

64%36%

Bearish Bullish

67%33%

News

Stocktwits